{"id":"NCT00606632","sponsor":"Heidelberg Pharma AG","briefTitle":"Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody","officialTitle":"A Comparative Study of PET/CT Versus Diagnostic CT for the Detection of Clear Cell Renal Cell Carcinoma in Pre-surgical Patients With Renal Masses Using Iodine-124 Labeled Chimeric G250 (124I-cG250)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-03","primaryCompletion":"2009-11","completion":"2009-12","firstPosted":"2008-02-04","resultsPosted":"2014-04-14","lastUpdate":"2018-10-02"},"enrollment":226,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"DIAGNOSTIC"},"conditions":["Renal Cell Carcinoma","Kidney Cancer"],"interventions":[{"type":"DRUG","name":"124-Iodine-cG250 (124I-cG250)","otherNames":["Ca9-SCAN"]},{"type":"PROCEDURE","name":"CT","otherNames":[]}],"arms":[{"label":"124-Iodine-cG250 (124I-cG250)","type":"OTHER"}],"summary":"This is a multicenter Phase III study to demonstrate the diagnostic utility of 124I-cG250 PET/CT pre-surgical imaging in patients with operable renal masses.","primaryOutcome":{"measure":"Sensitivity and Specificity of 124I-cG250 PET/CT Versus Diagnostic CT.","timeFrame":"6 months","effectByArm":[{"arm":"Sensitivity CT","deltaMin":0.76,"sd":null},{"arm":"Sensitivity PET/CT","deltaMin":0.86,"sd":null},{"arm":"Specificity PET/CT","deltaMin":0.86,"sd":null},{"arm":"Specificity CT","deltaMin":0.47,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.023"},{"comp":"OG002 vs OG003","p":"<0.01"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":16},"locations":{"siteCount":14,"countries":["United States"]},"refs":{"pmids":["17395103","23213092"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":33,"n":226},"commonTop":["Nausea","Procedural pain","Constipation","Fatigue","Abdominal pain"]}}